Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Open-label, Randomized, Study to Assess the Onset of Platelet Aggregation Inhibition After a Single Subcutaneous Injection of ACT-246475 in Adults With Acute Myocardial Infarction

Trial Profile

A Multi-center, Open-label, Randomized, Study to Assess the Onset of Platelet Aggregation Inhibition After a Single Subcutaneous Injection of ACT-246475 in Adults With Acute Myocardial Infarction

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Selatogrel (Primary)
  • Indications Myocardial infarction
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Idorsia Pharmaceuticals

Most Recent Events

  • 26 May 2020 Primary endpoint has not been met. (The response to treatment, defined for each patient as a PRU value 100 at 30 min post-dose.)
  • 26 May 2020 Primary endpoint has been met. (The response to treatment, defined for each patient as a PRU value 100 at 30 min post-dose.)
  • 26 May 2020 Results published in the Journal of the American College of Cardiology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top